文献速递神经肿瘤

H3K27me3表达缺失在复发1级和2级脑膜瘤中富集,并维持作为分层进展风险的生物标志物

Loss of H3K27me3 expression enriches in recurrent grade 1&2 meningiomas and maintains as a biomarker stratifying progression risk.
PubMed 文献 · J Neurooncol · 2022-11-03

回顾性单中心队列研究显示,复发1级和2级脑膜瘤中H3K27me3缺失频率高于原发脑膜瘤,且缺失与更早再次复发相关;复发1级脑膜瘤中H3K27me3缺失是无进展生存期的独立预后因素。

要点

  • 复发1级和2级脑膜瘤中H3K27me3缺失频率均高于原发脑膜瘤(p<0.001)。
  • H3K27me3缺失与复发1级和2级脑膜瘤更早再次复发相关(p<0.001)。
  • 复发1级脑膜瘤中H3K27me3缺失是无进展生存期的独立预后因素(p=0.005)。

核心结论

  • 与原发性脑膜瘤相比,复发性脑膜瘤更常见H3K27me3表达缺失,且复发肿瘤进展过程中可发生进一步缺失。
  • H3K27me3缺失预测复发1级和2级脑膜瘤更短的无进展生存期,支持在复发WHO 1级和2级脑膜瘤中进行H3K27me3临床检测。

研究设计与样本

  • 回顾性单中心队列研究,纳入2009年至2013年接受复发性1级(N=132)和2级(N=32)脑膜瘤切除术的患者。
  • 对45例随访期间肿瘤复发并接受切除术的患者进行H3K27me3染色,以评估肿瘤进展过程中的H3K27me3变化。
  • 分析了H3K27me3染色与临床参数的相关性,并进行了生存分析。

主要发现

  • 83例患者观察到H3K27me3表达缺失,包括63例1级(47.7%)和20例2级(62.5%)患者。
  • 复发1级(p<0.001)和2级(p<0.001)脑膜瘤的H3K27me3缺失频率均高于原发脑膜瘤。
  • 27例H3K27me3保留的肿瘤中,8例在再次复发时出现H3K27me3缺失(29.6%);18例H3K27me3缺失的肿瘤在疾病进展中未观察到H3K27me3获得。
  • H3K27me3表达缺失与复发1级和2级脑膜瘤更早再次复发相关(p<0.001),并且是复发1级脑膜瘤无进展生存期的独立预后因素(p=0.005)。

临床怎么用

  • 作者认为,研究结果支持在复发WHO 1级和2级脑膜瘤中进行H3K27me3临床检测。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To determine if loss of H3K27me3 could predict higher risk of re-recurrence in recurrent meningiomas. METHODS: A retrospective, single-center cohort study was performed for patients who underwent resection of recurrent grade 1 (N = 132) &2 (N = 32) meningiomas from 2009 to 2013. Association of H3K27me3 staining and clinical parameters was analyzed. Additionally, H3K27me3 staining was performed from 45 patients whose tumors recurred and were resected during the follow-up, to evaluate H3K27me3 change during tumor progression. Survival analysis was performed as well. RESULTS: Loss of H3K27me3 expression was observed in 83 patients, comprising 63 grade 1 (47.7%) and 20 grade 2 patients (62.5%). Both grade 1 (p < 0.001) and grade 2 recurrent meningiomas (p < 0.001) had a higher frequency of H3K27me3 loss, compared to de novo meningiomas. 8 of 27 tumors with retained H3K27me3 lost H3K27me3 during re-recurrence (29.6%), while no gain of H3K27me3 was observed in progressive disease from 18 tumors with H3K27me3 loss. Loss of H3K27me3 expression was associated with an earlier re-recurrence in recurrent meningiomas grade 1 and 2 (p < 0.001), and was an independent prognostic factor for PFS in recurrent grade 1 meningiomas (p = 0.005). CONCLUSION: Compared to primary meningiomas, recurrent meningiomas more predominantly had loss of H3K27me3 expression, and further loss can occur during the progression of recurrent tumors. Our results further demonstrated that loss of H3K27me3 predicted shorter PFS in recurrent grade 1 and grade 2 meningiomas. Our work thus supports clinical testing of H3K27me3 in recurrent meningiomas WHO grade 1 and 2.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Hua L, Ren L, Wu Q, et al. Loss of H3K27me3 expression enriches in recurrent grade 1&2 meningiomas and maintains as a biomarker stratifying progression risk. J Neurooncol. 2022. PMID: 36329368. doi:10.1007/s11060-022-04169-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。